Dominion's second-quarter earnings fell 55% to $340 million, but the decline says little about the regulated business. The quarter absorbed an $820 million impairment of nonregulated renewable natural gas facilities. It also absorbed costs the utility expects not to recover from customers on 100% of the CVOW Commercial Project. Strip out those items and the underlying story is a regulated franchise earning more than a year ago, with Virginia Power net income up 12% in the quarter and up 20% year-to-date. The central question for the investment is whether the regulated asset base and the authorized returns attached to it grow fast enough to outrun the debt, impairments, and regulatory disallowances Dominion has been booking. The market prices that question as a modest multiple on normalized earnings, with a trailing value of 22.78. The forward value of 17.26 implies the market expects earnings to recover from the impairment-heavy second quarter. The investment could prove wrong in either direction. A Virginia biennial review that resets returns below the rider-driven path changes the math on the multiple. So does a rate-base build that stalls on debt cost and regulatory disallowance.
The two segments that matter most are Dominion Energy Virginia and the nonregulated activities that sit above it. Virginia Power delivered 24.7 million MWh of electricity in the quarter. That is up 4% year-over-year. The segment serves roughly 2.8 million electric distribution accounts. The 2025 Biennial Review lifted Virginia Power's revenue base in the quarter. Rider equity returns from capital investment added a further $79 million of net income in the quarter. That figure scaled to $163 million year-to-date. Against that, the nonregulated book of renewable natural gas facilities produced the $820 million impairment, and the CVOW Commercial Project produced the non-recovery charge. The investment decision therefore turns on two variables. How much authorized return the Virginia rate base generates as it compounds, and how quickly the nonregulated impairments stop. The third variable is the cost of the debt that funds the rate base. That cost rose 10% in the quarter.